Yoon replaces 6 ministers ahead of his 3rd year, general election
US deploys fighter jets in S. Korea for air exercise in Singapore
S. Korea's economy grows 0.6% in Q3, unchanged from earlier estimate
S. Korea successfully tests solid-fuel space rocket
Another search targets opposition leader in corruption probe
Generational shift looms in SK leadership
[KH Explains] Why tighter US subsidy rules could boost Chinese firms
Majority of Korean office workers sleep deprived
US rejects NK's 'double standard' claim on Seoul's satellite launch
Province office raided in probe into wife of opposition leader
Samsung Biologics' market cap crashes over problematic accountingBy Yonhap
Published : May 5, 2018 - 11:11
The share price of the firm nosedived 26.3 percent over the previous three trade sessions, losing a whopping 8.5 trillion won ($7.8 billion) in terms of market cap.
The drop came after South Korea's financial watchdog on Tuesday tentatively concluded that Samsung BioLogics committed accounting fraud while assessing the value of another drug affiliate, Samsung Bioepis, in late 2015.
Following the move, Samsung BioLogics reported a whopping net profit of 1.9 trillion won in 2015, shifting from huge losses in the previous four years.
Other allegations include that the Korea Exchange lowered barriers to enter the main bourse to pave way for Samsung BioLogics' debut in 2016.
A day after the watchdog's announcement, shares of Samsung BioLogics dropped 17.21 percent in the following trade session. The market closed on Tuesday in South Korea for Labor Day.
It continued to lose ground over the rest of the week, closing at 359,500 won Friday, which compares to 488,000 won posted before the watchdog's announcement.
The company is currently in denial of the allegations. (Yonhap)
Korea unveils plan to tackle ailing mental health
[KH Explains] China ups OLED ante to take over Korean shares
6 outgoing ministers ‘strong candidates’ for general elections: ruling party